Drug giant GlaxoSmithKline is facing a mounting number of lawsuits alleging the off-label use of its anti-nausea drug Zofran to treat symptoms of morning sickness caused birth defects.
Langdon & Emison is representing clients nationwide in cases involving alleged Zofran-induced birth defects and is accepting potential new cases. Recent studies have linked a number of birth defects to Zofran, including but not limited to:
- Heart defects, including heart murmur or hole in the heart.
- Cleft lip or cleft palate.
Zofran, known generically as ondansetron, is an anti-nausea drug that is prescribed off-label to treat severe morning sickness during the first trimester of pregnancy; however, Zofran is not approved for use during pregnancy.
Zofran was developed by GlaxoSmithKline (GSK) and approved in the United States in 1991 to treat patients who experience nausea and vomiting from surgery or chemotherapy and radiation treatment.
However, doctors have increasingly prescribed Zofran to pregnant women who experience symptoms of severe morning sickness such as uncontrollable vomiting requiring hospitalization and severe dehydration and weight loss. By 2013, more than 1 million pregnant women per year were using Zofran.
Free Case Evaluation
If you or someone has a child born with a defect that may have been caused by Zofran use during pregnancy, contact Langdon & Emison for a free case evaluation at 1-800-397-4910 or by clicking on the chat box to the right. There is no charge to you unless we win your case for you.